Supaglutide injection

DRUG3 trials

Sponsors

Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.

Conditions

Diabetes Mellitus, Type 2Healthy VolunteersType2 Diabetes

Phase 1

A Study of the Efficacy and Safety of Supaglutide in Healthy Participants

CompletedNCT03745885

Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.Diabetes Mellitus, Type 2

Start: 2018-12-04End: 2019-12-13Updated: 2021-09-17

Drug Drug Interaction (DDI) Between Supaglutide and Digoxin or Metformin

CompletedNCT05694221

Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.Healthy Volunteers

Start: 2023-03-20End: 2023-08-17Updated: 2024-08-05

Phase 2

A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients(SUPER-1)

CompletedNCT04994288

Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.Type2 Diabetes

Start: 2021-08-03End: 2023-08-16Updated: 2024-08-07

Related Papers

Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial.

2025-11-21

Exposure-Response Analysis of Efsubaglutide Alfa in Patients with Type 2 Diabetes Mellitus.

2025-10-17

Effect of Efsubaglutide Alfa on the Pharmacokinetics of Metformin and Digoxin in Healthy Participants.

2025-06-30

Population Pharmacokinetics of Efsubaglutide Alfa in Healthy Subjects and Subjects with Type 2 Diabetes.

2025-02-177 citations

757-P: Efficacy and Safety of Supaglutide Monotherapy in Patients with Type 2 Diabetes

Diabetes2023-06-203 citations